PeptideStack
5.2kquestions
20kanswers
220users

Is oral semaglutide at 1 mg/mL stable enough for four weeks of multi-withdrawal use?

Asked 3 Mar 2026Modified 30 days agoViewed 7.3k times
12

The particulars: oral semaglutide · 1 mg/mL · four weeks.

Somebody stated this to me confidently and I would like to check it before repeating it.

I would accept a well-reasoned negative answer over a poorly sourced positive one.

Is this actually true, and what is the evidence?

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
bacteriostatic-water
bacteriostatic-water

Water for injection containing roughly 0.9 per cent benzyl alcohol as a bacteriostatic agent. It suppresses growth in a multiple-withdrawal vial;…

149 questions
shelf-life
shelf-life

How long a preparation remains within specification: labelled expiry for a sealed lyophilised vial, beyond-use dating after reconstitution, and…

327 questions
oral-glp1
oral-glp1

Oral routes for GLP-1 receptor agonism: peptide formulations rescued by absorption enhancers such as SNAC, and true small molecules that need no…

219 questions
shareeditfollowflag
SS
askedswirl_dont_shake10k143 Mar 2026

2 Answers

Sorted by votes
9

four weeks is 28 days and, on a weekly schedule, 4 stopper punctures out of one vial at 1 mg/mL. Set the chemical question aside for a moment, because the puncture count is the one with a convention attached: 28 days is 1 times the twenty-eight days conventionally allowed for a preserved multi-dose preparation once it has been entered. Chemically, 1 mg/mL is high enough that adsorption to the glass is a rounding error and low enough that it is not protecting you from anything. What 4 withdrawals do add is 4 opportunities to introduce air, 4 coring events on the same stopper, and a headspace that grows with every draw — none of which show up on a certificate and all of which are avoided by splitting into aliquots at reconstitution.

The honest answer is that most reported "degradation" is adsorption and dilution error rather than chemistry.

Deamidation converts asparagine or glutamine to the corresponding acid via a succinimide intermediate, adding one dalton. It is base-catalysed, accelerates above neutral pH and is the dominant aqueous pathway for many peptides.

Freeze-thaw cycling drives aggregation through concentration at the ice interface and pH shifts as buffer components crystallise out at different rates. Each cycle costs something.

The caveat is that none of these pathways can be seen by looking at a vial, and a clear solution can be substantially degraded.

Cold, dry, dark, still. Those four words cover most of the mitigation.

shareimprove this answerflag
OB
answeredone_ml_bac18k2726 Jun 2026
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
7

The relevant point is that a mass shift of plus one dalton is deamidation and plus sixteen is oxidation, so degradation is often visible in a mass spectrum if anyone looks.

Hydrolysis cleaves the backbone, most readily at aspartate-proline and aspartate-glycine sequences, and is acid-catalysed. In a dry solid it barely proceeds at all.

It helps to be literal here: adsorption onto glass and plastic is significant at low concentrations — micrograms per millilitre — and negligible at milligrams per millilitre. It is the usual explanation for an apparent loss in a dilute preparation.

Sequence determines which pathways apply, so general statements are general.

At dilute concentrations, suspect adsorption before you suspect chemistry.

edited 30 Jun 2026 by tandem_gradient — added a caveat about sampling

shareimprove this answerflag
TG
answeredtandem_gradient61k24815 Jun 2026

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.